My Personal CFO LLC’s Exact Sciences EXAS Stock Holding History

My Personal CFO LLC’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6	Closed	-$297	–	319
2022 Q4	$297	Buy	+6	New	+$245	﹤0.01%	833

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

My Personal CFO LLC's EXAS Position: Q1 2023 in Review

My Personal CFO LLC sold out of Exact Sciences (EXAS) in Q1 2023, closing a stake of 6 shares — an estimated $297 sold.

My Personal CFO LLC first reported a position in EXAS in Q4 2022 and held it in 1 quarter. The position peaked at $297 in Q4 2022. 583 funds tracked by Wall St. Rank hold EXAS as of Q1 2023.

My Personal CFO LLC reported no remaining Exact Sciences position as of Q1 2023 after selling out during the quarter.
My Personal CFO LLC sold 6 Exact Sciences shares in Q1 2023, an estimated $297.
My Personal CFO LLC first reported a position in Exact Sciences in Q4 2022 and held it in 1 quarter.
My Personal CFO LLC's Exact Sciences position peaked at $297 in Q4 2022.
583 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2023.

Based on My Personal CFO LLC's 13F filing for Q1 2023, filed 21 Apr 2023.